TP53 and neoplasm: However, in patients with a history of more than one colorectal primary tumour and interval treatment, there was evidence for discordance in TP53. These examples demonstrate that relying on a single tumour biopsy may lead to sampling bias in some cases and risk missing potentially therapeutically relevant lesions or contribute to the allocation of a mutation as actionable without establishing clonal dominance [28].